Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam and Remifentanil Interaction Study
NCT04670471Phase 1Completed
- Sponsor
- PAION AG
- Start
- Apr 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of remimazolam in general anesthesia (4 arms), sponsored by PAION AG. Primary endpoint: Exposure-response model for MOAA/S at 3 weeks. Started Apr 2021; status: completed.
02
Drugs
remimazolam
03
Conditions
general anesthesia
Beyond the preview
Go deeper on NCT04670471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04670471.